| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 383,622 | 383,462 |
| Net increase in cash, cash equivalents and restricted cash | 103,811 | 320,736 |
| Cash and cash equivalents at beginning of period | 196,177 | - |
| Cash and cash equivalents at end of period | 299,988 | - |
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. (CDTX)